Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
Shockwave Medical, Inc.
Study ID
NCT07512128
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Carotid Artery Calcification
  • Carotid Artery Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carotid Intravascular Lithotripsy — DEVICE
    The Shockwave Medical Intravascular Lithotripsy (IVL) System with the Shockwave SkyRunner Carotid IVL Catheter is intended for lithotripsy- enhanced balloon dilatation of calcified lesions in the carotid arteries prior to stenting. Not for use treating massive exophytic (mushroom-like) or irregular endoluminal carotid calcification, or in the coronary or cerebral arteries.

Study Details

Prospective, Multi-center, Single-arm Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral stenting (SKYWARD Trans-Femoral IDE Study)

Key Dates

First listed
Apr 6, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2032

Study Design

Enrollment
185 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Calcified Carotid Artery
    Up to 160 subjects for the primary analysis cohort, with 25 additional roll-in subjects, with calcified carotid arteries to be treated with intravascular lithotripsy (IVL) prior to stenting with commercially available trans-femoral stent systems in patients at high risk for complications from carotid endarterectomy (CEA) will be enrolled in the study.

Primary Outcome Measure

Primary Endpoint: Composite endpoint with death, stroke, or myocardial infarction (MI) [Safety] [ Time Frame: 30 days post procedure ]

Central Contacts

Locations (25)

FacilityCityStateZIPSite coordinators
Pulse InstituteScottsdaleArizona85258
Anita Ramaiah
(480) 912-4747
Venkatesh Ramaiah (PRINCIPAL_INVESTIGATOR)
HCA HealthOne SwedishAuroraColorado80012
Saad Syed, MD
571-685-3551
Ehrin Armstrong (PRINCIPAL_INVESTIGATOR)
Ascension St. Vincent'sJacksonvilleFlorida32204
Arianna Wright
904-308-5761
Samer Garas (PRINCIPAL_INVESTIGATOR)
Baptist Health Research InstituteJacksonvilleFlorida32207
Sarah Jennings
904-202-7063
Ricardo Hanel (PRINCIPAL_INVESTIGATOR)
Ascension Sacred HeartPensacolaFlorida32504
Carole Funderburk
850-416-6196
Rohit Amin (PRINCIPAL_INVESTIGATOR)
Wellstar Kennestone HospitalMariettaGeorgia30060
Marianne Bain
470-793-4040
Rishi Gupta (PRINCIPAL_INVESTIGATOR)
Willis-KnightonShreveportLouisiana71103
Briana Barrow
318-212-8671
Ashish Sonig (PRINCIPAL_INVESTIGATOR)
Mercy South HospitalSt LouisMissouri63128
Ruth Fauska
314-525-1937
Anish Thomas (PRINCIPAL_INVESTIGATOR)
University of Buffalo NeurosurgeryBuffaloNew York14203
Ellen Carl
716-218-1000
Adnan Siddiqui (PRINCIPAL_INVESTIGATOR)
Mount SinaiNew YorkNew York10029
Emily Svendsen
212-241-3238
Daryl Goldman (PRINCIPAL_INVESTIGATOR)
St. Francis Hospital & Heart CenterRoslynNew York11576
Michele Piscitelli-Sharp
516-562-6790
Lawrence Garcia (PRINCIPAL_INVESTIGATOR)
NC Heart and VascularRaleighNorth Carolina27607
James Pierre-Louis
919-784-3100
Ravish Sachar (PRINCIPAL_INVESTIGATOR)
WakeMedRaleighNorth Carolina27610
LaMonica Daniel
919-350-7438
Siva Ketha (PRINCIPAL_INVESTIGATOR)
Cleveland ClinicClevelandOhio44195
Laurie Ann Moennich
216-444-2106
Sean Lyden (PRINCIPAL_INVESTIGATOR)
University of Oklahoma Health Sciences CenterOklahoma CityOklahoma73104
Sanaa Hameed
405-271-8001
Hakeem Shakir (PRINCIPAL_INVESTIGATOR)
Main Line Health SystemWynnewoodPennsylvania19096
Ann Marie Chikowski
(610) 645-2000
Sarang Mangalmurti (PRINCIPAL_INVESTIGATOR)
The Miriam HospitalProvidenceRhode Island02906
Lina Felix
401-793-4105
Peter Soukas (PRINCIPAL_INVESTIGATOR)
Lexington HealthWest ColumbiaSouth Carolina29169
Linda Sherriff
803-935-8374
Mathew Wooster (PRINCIPAL_INVESTIGATOR)
North Central Heart, Avera Heart HospitalSioux FallsSouth Dakota57108
Patty Eisenbraun
605-977-5336
Michael Bacharach (PRINCIPAL_INVESTIGATOR)
Stern Cardiovascular CenterGermantownTennessee38138
Kari Fondren
901-271-4062
James Klemis (PRINCIPAL_INVESTIGATOR)
Wellmont Cardiology Services - CVA Heart InstituteKingsportTennessee37660
Terrie Walker
423-230-5643
Christopher Metzger (PRINCIPAL_INVESTIGATOR)
Tennova HealthcareKnoxvilleTennessee37934-
Houston MethodistHoustonTexas77030
Nhu Nguyen
346-356-7065
Alpesh Shah (PRINCIPAL_INVESTIGATOR)
UT MD Anderson Cancer CenterHoustonTexas77030
Maria Briones Dimayuga
832-792-1692
Stephen Chen (PRINCIPAL_INVESTIGATOR)
Baylor Scott & White PlanoPlanoTexas75093
Osniel Gonzalez Ramos
469081402000
Sameh Sayfo (PRINCIPAL_INVESTIGATOR)

Find similar trials in Scottsdale, AZ

Related Studies